en · de · es · pt
cardarine-notes.peptides6823.com › Topic › Background And Regulatory History — Beginner to Advanced

Background And Regulatory History — Beginner to Advanced

By Editorial Desk · published 2026-06-20 · last reviewed 2026-07-10 · Topic

A practical reference on unapproved substance: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-07-10. Anything still debated is marked as such rather than presented as settled.

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Background and Regulatory Status

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Cardarine at a glance

PropertyValueNotes
Common nameCardarineCommon internet and media name.
Research codeGW501516Also written GW-1516.
Drug classPPARδ agonistNot a selective androgen receptor modulator.
Development statusDiscontinuedClinical development halted after rodent cancer findings.
Regulatory statusProhibited in sportListed by WADA; not approved as medicine.

Reference notes

A suture is a type of fibrous joint that is only found in the skull (cranial suture). The bones are bound together by Sharpey's fibres. A tiny amount of movement is permitted at sutures, which contributes to the compliance and elasticity of the skull. These joints are synarthroses. It is normal for many of the bones of the skull to remain unfused at birth. The fusion of the skull's bones before birth is known as craniosynostosis. The term "fontanelle" is used to describe the resulting "soft spots". The relative positions of the bones continue to change during the life of the adult (though less rapidly), which can provide useful information in forensics and archaeology. In old age, cranial sutures may ossify (turn to bone) completely. The joints between the teeth and jaws (gomphoses) and the joint between the mandible and the cranium, the temporomandibular joint, form the only non-sutured joints in the skull.

=== Singles/EPs/demos === "Children Break" (1988) Barging Into the Presence of God EP (September 1989) UK Indie No. 3 UK No. 135 Half-Life EP (October 1990), 12" contains a bonus spoken-word track "Colour of the Sky" UK No. 86 "Kinky Love" (1991) (12" issued as Flesh Balloon EP) (June 1991) UK No. 72 "Porpoise" (1991) "Throwing Back the Apple" (May 1992) UK No. 93 Fine Friend EP (August 1994) "Fine Friend" (1994), US promo including "One Blue Hill" live acoustic @ KCRW "Angel (Will You Be My)" (1995), US promo

==== V-RG ==== RABORAL V-RG (Boehringer Ingelheim, Duluth, GA, USA) is a vaccinia virus (originally a smallpox vaccine) modified to express rabies glycoprotein. V-RG has been proven safe in over 60 animal species including cats and dogs. It is only approved for wildlife and sold to federal agencies. V-RG has been the only ORV licensed in the US for rabies virus management since 1997. V-RG baits consist of a small packet containing the oral vaccine which is then either coated in a fishmeal paste or encased in a fishmeal-polymer block.

Zhang's tactics included propaganda, intelligence-gathering, and involvement in the opium trade, while Liu fought back with counter-propaganda and appointing loyalist magistrates who frustrated Zhang's work. Liu triumphed in 1942 when the 36th Division was moved to the Yunnanese front, and Zhang was transferred back to Chongqing in 1946. Zhang's presence was replaced by He Guoguang, but Liu continued frustrating Nationalist centralization attempts. In 1944 during Operation Ichi-Go, there was once again talk of moving the capital to Xichang, encouraged by American General Wedermeyer, but this was abandoned after the Japanese offensive stalled. In late 1942, Chiang ordered Liu and Ma Bufang of Qinghai to mobilize for a campaign against Tibet. Liu was suspicious of the Nationalist leader's motivations, dispatching his chief of staff Wu Peiying (伍培英) to Chongqing to plan for the invasion and negotiate with Chiang. According to Liu's 1990 biography, he had asked for a fully-equipped division of 10,000 troops, cavalry, and engineers; another division to maintain order, winter equipment, around 10,000 yaks, additional food supplies, and a truck route from Sichuan to Xikang. Liu also requested that he take sole command of these reinforcements. Later archival documents would confirm Liu's suspicions that the campaign was a plot; once Liu had mobilized his forces, Chiang was to send 30,000 men under his personal command into Xikang and depose Liu. Due to Liu's stalling tactics as well as Allied pressure, the campaign did not materialize.

Sources: en.wikipedia.org

Related pages on this site

Notes from published material

== Research and innovation == BioDuro is involved in developing data-driven and automated workflows intended to accelerate discovery timelines. The company has partnered with technology firms, including Atombeat, to integrate AI-supported peptide-design platforms with high-throughput peptide synthesis and iterative screening workflows. According to the company, these approaches are designed to reduce design–test cycles in peptide and bioconjugate programs; independent evaluation of the platform’s performance is still limited in publicly available literature.

=== Clonidine overdose === Naloxone can also be used as an antidote in an overdose of clonidine, a medication that lowers blood pressure. Clonidine overdoses are of special relevance for children, in whom even small doses can cause significant harm. However, there is controversy regarding naloxone's efficacy in treating the symptoms of clonidine overdose, namely slow heart rate, low blood pressure, and confusion/somnolence. Case reports that used doses of 0.1 mg/kg (maximum of 2 mg/dose) repeated every 1–2 minutes (10 mg total dose) have shown inconsistent benefit. As the doses used throughout the literature vary, it is difficult to form a conclusion regarding the benefit of naloxone in this setting. The mechanism for naloxone's proposed benefit in clonidine overdose is unclear. Still, it has been suggested that endogenous opioid receptors mediate the sympathetic nervous system in the brain and elsewhere in the body.

=== Legal status === The US Food and Drug Administration (FDA) approved trastuzumab deruxtecan in December 2019. The application for trastuzumab deruxtecan was granted accelerated approval, fast track designation, and breakthrough therapy designation. The FDA granted the approval of Enhertu to Daiichi Sankyo. In December 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Enhertu, intended for the treatment of metastatic HER2-positive breast cancer. Trastuzumab deruxtecan was reviewed under EMA's accelerated assessment program. The applicant for this medicinal product is Daiichi Sankyo Europe GmbH. Trastuzumab deruxtecan was approved for medical use in the European Union in January 2021. In January 2021, the FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In October 2021, the Australian Therapeutic Goods Administration approved trastuzumab deruxtecan for provisional registration indicated for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti HER2-based regimens.

== In vivo activity == NR58-3.14.3 also inhibits the recruitment of leukocytes (macrophages, T cells, B cells) due to the chemokine CCL2 in rat skin. A similar effect was observed using Lipopolysaccharide (LPS) instead of CCL2 (macrophages, neutrophils, T cells, B cells). In addition NR58-3.14.3 inhibits LPS-induced accumulation of tumour necrosis factor-α (TNF-α). This is consistent with the peptide acting as a chemokine inhibitor up-steam of TNF-α productsion and anti-inflammatory in vivo. The cyclic peptide NR58-3.14.3 was shown to be a powerful anti-inflammatory agent in vivo inhibiting inflammation in a number of disease models such as atherosclerosis, ischemia, lung disease, surgical adhesions, endometriosis and pulmonary graft-versus-host disease. It has been suggested that blockage of chemokine function using these molecules should not have a detrimental toxicological effect.

=== Others, associated with the city === Rex Cherryman (1896–1928), American actor, died here Jean-Paul Sartre (1905–1980), philosopher, taught at the Lycée François-Ier Patrick Demarchelier (1943–2022), fashion photographer, spent his childhood in Le Havre Christine Lagarde (born 1956), IMF managing director, grew up in Le Havre René Viénet (born 1944), sinologist Suzzane Fontaine (1894-1979), paternal grandmother of Pope Leo XIV

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a selective androgen receptor modulator?

No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.

Why did clinical development stop?

Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.

Is cardarine approved for medical use?

No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Network